2023
A pilot randomized controlled trial of ketamine in Borderline Personality Disorder
Fineberg S, Choi E, Shapiro-Thompson R, Dhaliwal K, Neustadter E, Sakheim M, Null K, Trujillo-Diaz D, Rondeau J, Pittaro G, Peters J, Corlett P, Krystal J. A pilot randomized controlled trial of ketamine in Borderline Personality Disorder. Neuropsychopharmacology 2023, 48: 991-999. PMID: 36804489, PMCID: PMC10209175, DOI: 10.1038/s41386-023-01540-4.Peer-Reviewed Original ResearchConceptsBorderline personality disorderSecondary outcome measuresOutcome measuresSocio-occupational functioningSuicidal ideationPilot studyTrial of ketaminePersonality disorderInfusion of ketaminePrimary outcome measureEffects of ketamineMidazolam groupAdverse eventsKetamine groupClinical benefitMood symptomsKetamineFDA approvalDrug midazolamInfusionBPD symptomsLarger studyDepressed moodSymptomsChronic moodXR-buprenorphine for OUD in a Correctional Setting
Neustadter, EN. XR-buprenorphine for OUD in a Correctional Setting. The Carlat Addiction Treatment Report. 2023, Sept/Oct.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsWorking with placebo and nocebo effects: Psychiatric prescribing beyond the mind-body split.
Neustadter, ES, Shapiro-Thompson R, Fineberg SK. Working with placebo and nocebo effects: Psychiatric prescribing beyond the mind-body split. In Gallagher, K, Cahill, J, editors. Psychiatric Prescribing: The How, The Why, and the Why Not. Cambridge, UK: Cambridge University Press: in pressChapters
2021
Mentalization and embodied selfhood in Borderline Personality Disorder.
Neustadter ES, Fotopoulou A, Steinfeld M, Fineberg SK. Mentalization and embodied selfhood in Borderline Personality Disorder. Journal Of Consciousness Studies 2021, 28: 126-157. PMID: 34987307, PMCID: PMC7612160.Peer-Reviewed Original Research
2019
Working in Recovery: A Medical Student’s Experience
Neustadter E. Working in Recovery: A Medical Student’s Experience. Psychiatric Services 2019, 70: 853-854. PMID: 31337327, DOI: 10.1176/appi.ps.701001.Commentaries, Editorials and LettersPractical Tips for Implementing a Student-Led Reflective Writing Workshop Series
Shahu A, Thomas AR, Neustadter E, Reisman A. Practical Tips for Implementing a Student-Led Reflective Writing Workshop Series. Medical Science Educator 2019, 29: 863-869. PMID: 34457552, PMCID: PMC8368934, DOI: 10.1007/s40670-019-00753-x.Peer-Reviewed Educational MaterialsInduced illusory body ownership in borderline personality disorder
Neustadter ES, Fineberg SK, Leavitt J, Carr MM, Corlett PR. Induced illusory body ownership in borderline personality disorder. Neuroscience Of Consciousness 2019, 2019: niz017. PMID: 31908849, PMCID: PMC6938263, DOI: 10.1093/nc/niz017.Peer-Reviewed Original Research
2017
Individuals with Borderline Personality Disorder show larger preferred social distance in live dyadic interactions
Fineberg SK, Leavitt J, Landry CD, Neustadter ES, Lesser RE, Stahl DS, Deutsch-Link S, Corlett PR. Individuals with Borderline Personality Disorder show larger preferred social distance in live dyadic interactions. Psychiatry Research 2017, 260: 384-390. PMID: 29248760, PMCID: PMC5972044, DOI: 10.1016/j.psychres.2017.11.054.Peer-Reviewed Original Research
2016
EEG and MEG probes of schizophrenia pathophysiology
Neustadter, ES, Mathiak, K, Turetsky, BI. EEG and MEG probes of schizophrenia pathophysiology. In Abel T, Nickl-Jockschat, T, editors. The Neurobiology of Cchizophrenia. London, UK: Academic Press: 2016; 213-236.Chapters
2015
Metastatic Colorectal Cancer: A Systematic Review of the Value of Current Therapies
Goldstein D, Zeichner S, Bartnik C, Neustadter E, Flowers C. Metastatic Colorectal Cancer: A Systematic Review of the Value of Current Therapies. Clinical Colorectal Cancer 2015, 15: 1-6. PMID: 26541320, PMCID: PMC4744531, DOI: 10.1016/j.clcc.2015.10.002.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsBevacizumabCamptothecinCetuximabColorectal NeoplasmsCost-Benefit AnalysisDrug CostsFluorouracilHumansIrinotecanLeucovorinNeoplasm MetastasisOrganoplatinum CompoundsOxaliplatinPanitumumabQuality-Adjusted Life YearsTreatment OutcomeUnited StatesConceptsMetastatic colorectal cancerCurrent treatment strategiesTreatment strategiesSystematic reviewIncremental cost-effectiveness ratioUS payer perspectiveHigher drug costsCost-effectiveness ratioCost-effective treatmentCost-effectiveness analysisColorectal cancerCurrent therapiesHigh-value treatmentsPayer perspectiveDrug costsVEGF pathwayUS FoodDrug AdministrationOlder agentsModern agentsSearch criteriaTreatmentPanitumumabCetuximabIrinotecan
2014
Is Prevention a Realistic Goal for Schizophrenia?
Kohler C, Borgmann-Winter K, Hurford I, Neustadter E, Yi J, Calkins M. Is Prevention a Realistic Goal for Schizophrenia? Current Psychiatry Reports 2014, 16: 439. PMID: 24566772, DOI: 10.1007/s11920-014-0439-y.Peer-Reviewed Original ResearchConceptsEarly clinical symptomsOnset of psychosisCertain clinical presentationsLarge epidemiological studiesClinical presentationClinical symptomsClinical riskEpidemiological studiesSchizophrenia phenotypePsychosisMultidisciplinary approachRisk stateSchizophreniaRealistic goalsRecent studiesOnsetSymptomsPrevention